Description: K252a: Cell permeable protein kinase inhibitor
Solubility ( literature ): Readily soluble in chloroform, acetonitrile, acetone, dioxane, tetrahydrofuran, pyridine;soluble in ethanol, methanol, 1-propanol, ethyl acetate and n-butanol; insoluble in water, 2-propanol
Applications: K252a is a highly potent cell permeable inhibitor of CaM kinase and phosphorylase kinase . At high concentrations it also inhibitors of serine/threonine protein kinases. K252a inhibits tyrosine phosphorylation of Trk A induced by NGF K252a is reported to promote myogenic differentiation in C2 mouse myoblasts
Composition: Ingredient type Fermentek product
Disclaimer: For Research use only, Not for Human or Drug use, Not extracted from humans or animals, Refer to MSDS for further safety and handling instructions
Names and identifiers: RTECS NZ0550000
Pub 1: WO Application WO2017053983A1 Quantifying met protein for cancer treatment ; Anti-cancer therapeutic agents designed to specifically inhibit the function and/or reduce the presence of the Met protein include: MET kinase inhibitors such as K252a (Fermentek Biotechnology) US Patent Application for MODULATORS OF CELL DEATH PROCESSES Patent Application (Application #20180071280). URIFER LTD; Inventors: Yoav ELKIS, Sally SHPUNGIN, Uri NIR
Source: Nocardiopsis sp
Chemical name:
InChl Key: KOZFSFOOLUUIGY-IYYJOCMQSA-N